A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
Mostly cloudy overnight, but as low pressure systems feed in as the week goes on an unsettled period can be expected.
The hunt for murder suspect Jed Allen has ended after police found his body two days after discovering his mother, stepdad and sister dead.
Ben Stokes was in the thick of the action again as England completed a once highly improbable victory in the first Test aganist New Zealand